#Canada #Medical Devices #Biocomposites #Keele #SYNICEM™

Biocomposites Expands SYNICEM™ Spacer Launch to Canada

Biocomposites, a prominent player in the international medical devices sector, has recently announced the introduction of its innovative SYNICEM™ preformed spacers in Canada. This extension follows the successful launch of these products in the U.S., marking another significant step in the company's commitment to enhancing infection management for orthopedic procedures.

Overview of SYNICEM™ Spacers

The SYNICEM™ spacers are preformed and loaded with antibiotics, specifically designed to support surgeons in managing infections during two-stage revision surgeries for the hip, knee, and shoulder joints. The primary goals of these spacers are to maintain joint stability, preserve articular spaces, and ensure proper limb length during surgical procedures. By utilizing these sophisticated devices, healthcare professionals can effectively tackle bacterial infections that are sensitive to gentamicin, a critical component in many antibiotic treatments.

One of the key advantages of SYNICEM™ spacers is their precision engineering, providing consistent and uniform structural integrity. This means that each spacer is sterile and ready to use in under a minute, drastically reducing the time and mechanical risks associated with traditional handmade or intra-operatively molded spacers.

Variety and Flexibility

The SYNICEM™ range offers an extensive selection of sizes and styles, allowing for flexibility based on individual patient needs. Surgeons can choose from different designs, including the Charnley and Müller hip spacer variations, along with distinct geometries for left and right knees. With over 20 years of successful global use across more than 70 countries, these spacers have established a reputation for saving operative time and managing complex infection cases effectively.

Statements from Leadership

Michael Harris, CEO of Biocomposites, expressed pride in making these advanced products available in Canada so soon after their U.S. introduction. He stated, "The quality and consistency of the SYNICEM™ spacer range reflect our enduring focus on precision engineering and dependable performance. We aim to support clinicians and improve care for patients with complex needs." Harris's statement highlights the company's dedication to innovation and clinical excellence.

About Biocomposites

Biocomposites is recognized globally for engineering cutting-edge products that excel in infection management related to bone and soft tissues. Headquartered in Keele, UK, the company operates across Europe, South America, the USA, Canada, China, and India. Renowned for their development of calcium compounds and bone cements targeted at surgical applications, Biocomposites' products are involved in over 1 million procedures annually, addressing infection risks across various medical specialties, including orthopedics, trauma, and sports medicine.

For more information about Biocomposites and its product offerings, visit biocomposites.com.

This latest move to introduce SYNICEM™ spacers in Canada highlights Biocomposites' commitment to expanding its global footprint while addressing critical needs in infection control and patient care within the orthopedic surgical landscape.